Studies assessing plasma levels of SGLT2 inhibitors and ketone bodies (β-hydroxybutyrate, acetoacetate, and acetone) before and after co-prescription of SGLT2 inhibitors with inhibitors of proximal tubular organic anion transporters in healthy volunteers and in people with diabetes mellitus would be informative. Here, SLC5A2 is linked to diabetes mellitus.